ClinicalTrials.Veeva

Menu

Transcranial Direct/ Alternating Current Stimulation for Parkinson's Disease Treatment

A

Anhui Medical University

Status

Completed

Conditions

tACS
tDCS

Treatments

Device: sham
Device: tDCS
Device: tACS

Study type

Interventional

Funder types

Other

Identifiers

NCT05678725
tAtDComparePD

Details and patient eligibility

About

To investigate the difference in the treatment efficacy between transcranial direct current stimulation and transcranial alternating current stimulation on Parkinson's disease, including the improvements in the motor, cognitive, and underlying neural mechanisms behind differences in efficacy by electroencephalography (EEG).

Full description

All patients underwent a medical evaluation that include physical examinations and routine laboratory studies before and after stimulation sessions. Patients were randomly allocated to tACS, tDCS, and sham groups. There are about 20 patients in each group. Allocation was by computer generating random numbers. The decision to enroll a patient was always made prior to randomization. Patients were studied using a double-blind design. Study participants, clinical raters, and all personnel responsible for the clinical care of the patient remained masked to allocated conditions and allocation parameters. Only stimulation administrators had access to the randomization list; they had minimal contact with the patients, and no role in assessing the UPDRS(Unified Parkinson´s Disease Rating Scale), Hoehn & Yahr, and MoCA(Montreal Cognitive Assessment). Each patient would be treated for 20 minutes of transcranial electrical stimulation.

Before the stimulation session, UPDRS, Hoehn & Yahr, and MoCA were obtained by a trained investigator to assess the baseline severity of symptoms. The patients received electroencephalography (EEG) recorded during resting state for 5 minutes.

During the stimulation session, patients were asked to perform simple reaction tasks at the same time.

After the stimulation session, UPDRS, Hoehn & Yahr, and MoCA were obtained, as well as the Global Index of Safety(tES side effects) to assess adverse events of the treatment. The patients also received a measure of electroencephalography (EEG) recorded during the resting state.

Enrollment

60 patients

Sex

All

Ages

40 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • diagnosis of idiopathic PD according to the movement disorder society criteria
  • right-handed
  • no clinically known hearing or vision impairment
  • no history of epilepsy, dementia, other brain disorders apart from PD, severe internal organs disease, age-related frailty, etc.

Exclusion criteria

  • parkinsonism due to drugs, Cerebrovascular disease, encephalitis, poisoning, traumatic brain injury, etc.
  • Metal implants in the head (i.e., deep brain stimulator or aneurysm clips)
  • severe somatic or psychiatric disorders that require medication or routinely monitoring
  • participated in other interventional studies within the past 3 months

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

60 participants in 3 patient groups

Transcranial Alternating Current Stimulation
Active Comparator group
Description:
the alternating current stimulation lasted 20 mins and was delivered at 2mA (peak to peak) at 20Hz during the Simple Reaction Task(SRT), targeting the primary motor cortex. EEG should be acquired before and after the stimulation session.
Treatment:
Device: tACS
Transcranial Direct Current Stimulation
Active Comparator group
Description:
the direct current stimulation lasted 20 minutes and was delivered at 2mA during the SRT, targeting at the primary motor cortex. EEG should be acquired before and after the stimulation session.
Treatment:
Device: tDCS
Sham Group with No Actual Stimulation
Sham Comparator group
Description:
the procedure of this protocol lasted 20 minutes and was delivered at 0mA during the SRT. EEG should be acquired before and after the stimulation session.
Treatment:
Device: sham

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems